We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other best performing healthcare stocks to buy now.

Trump’s Healthcare Executive Order Brings a Win

On April 15, CNBC reported that President Trump’s healthcare-focused executive order brought in a win for the sector. Trump directed his health department to collaborate with Congress to revamp a law allowing Medicare to negotiate prescription drug prices. The announcement seeks to bring a change that the pharmaceutical company has lobbied for. Since the negotiation process is included in legislation, Trump’s executive order cannot implement the change itself. However, it directs Secretary of Health and Human Services Robert F. Kennedy Jr. to join hands with Congress and change it.

CNBC reported that drug makers have been working to delay the eligibility timeline for small-molecule drugs to be available for price negotiations by four years. This typically includes pills and most medications. This goes hand in hand with the 13-year wait until more complex biotech drugs are eligible for Medicare price negotiations.

Trump’s wide-ranging executive order also focuses on slashing healthcare costs. It comes a day after the administration instituted a national security report on the pharma industry. CNBC called the report “a precursor to sector-specific tariffs.”

READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds.

Medicare’s negotiating powers have been a subject of contention, as drug makers have opined that they would suppress innovation and have rallied against the time frame for negotiation eligibility for most drugs. The law now allows the government to negotiate prices for drugs with no competition, which includes complex biotech or biologic medications after 13 years on the market, but 9 years for their administration as capsules and pills.

Although they did not provide specifics, White House officials told reporters that other changes to the negotiation process would yield more savings than those attained during the first round under the Biden administration. While the Biden administration negotiated price cuts as steep as 79% for the first ten most expensive drugs to the Medicare program, the Trump administration would negotiate prices for the following 15 medications. This includes Pfizer’s cancer drugs Ibrance and Xtandi, as well as Novo Nordisk’s blockbuster diabetes and weight-loss treatments Ozempic and Wegovy.

Story Continues

Our Methodology

We used Finviz to screen healthcare stocks and selected the best performers based on their year-to-date (YTD) performance, as of May 9, 2025. We also included the number of hedge fund holders for each stock as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of year-to-date performance.

Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).Corcept Therapeutics Incorporated (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential

A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders.

Corcept Therapeutics Incorporated (NASDAQ:CORT)

YTD Performance: 39.37%

Number of Hedge Fund Holders: 29

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions. The company’s flagship product, Korlym, is FDA-approved for treating Cushing’s syndrome, a disorder caused by excessive cortisol production. The stock ranks eighth among the best-performing healthcare stocks to invest in.

On May 7, Canaccord Genuity analyst Edward Nash maintained their bullish stance on Corcept Therapeutics Incorporated (NASDAQ:CORT), giving it a Buy rating. The analyst reasoned that while the company experienced a weaker fiscal Q1 2025 due to shipping and packing complications, management is confident about its ability to resolve these issues and support strong performance in the coming quarters.

In fact, the analyst believes that Corcept Therapeutics Incorporated’s (NASDAQ:CORT) current weakness presents an attractive buying opportunity as its Korlym product is expected to see continuous revenue growth and growing demand.

In addition, the company’s expansion into oncology is a promising development, especially in its upcoming NDA filing for relacorilant in platinum-resistant ovarian cancer. According to the analyst, the drug has blockbuster potential following its potential approval, further augmenting Corcept Therapeutics Incorporated’s (NASDAQ:CORT) market opportunities.

Overall, CORT ranks 8th on our list of the best performing healthcare stocks to buy now. While we acknowledge the potential for CORT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CORT but trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments